Archemix, Sirna deal

The partners expanded a 2003 deal for RNAI to manufacture cGMP grade ARC183 anti-thrombin aptamer for preclinical, Phase I and Phase IIa studies (see BioCentury, Nov. 3, 2003). Under the new four-year...